Lung cancer patients may benefit from adding chemo to targeted therapy early
NCT ID NCT04769388
First seen Jan 12, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This study looks at whether adding chemotherapy to the targeted drug osimertinib works better than osimertinib alone for people with advanced lung cancer. It includes 80 patients whose cancer still shows a specific genetic change after three weeks of osimertinib. The goal is to see if the combination can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Conditions
Explore the condition pages connected to this study.